Please assess the completion status of the following clinical trial:

Trial Title: Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained before any trial related procedures~* Male patient with proven prostate cancer in need for endocrine treatment, except for neoadjuvant hormonal therapy~* ECOG score to be equal to or above 2~* Testosterone level within age-specific normal range~* PSA value equal to or above 2 ng/ml~* Life expectancy of at least 6 months~Exclusion Criteria:~* Previous or current hormonal treatment of prostate cancer~* Recent or current treatment with any drugs modifying the testosterone level~* Candidate for curative treatment such as prostatectomy or radiotherapy~* History of severe asthma, anaphylactic reactions or Quincke's Oedema~* Hypersensitivity towards any component of FE200486~* Cancer disease within the last ten years except for prostate cancer and some skin cancers~* Signs of liver impairment shown as elevated serum ALT or serum bilirubin~* Other laboratory abnormalities that judged by the investigator would interfere with the patients participation in the trial or the evaluation of the trial results~* Presenting with significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological, dermatological or infectious disorder. In addition any other condition such as excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator~* Mental incapacity or language barrier~* Having received an investigational product within the last 12 weeks preceding the trial~* Previous participation in this trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 120 mg (20 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (20 mg/mL)
- Degarelix 120 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (40 mg/mL)
- Degarelix 160 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 160 mg (40 mg/mL)
- Degarelix 200 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (40 mg/mL)
- Degarelix 200 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (60 mg/mL)
- Degarelix 240 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (40 mg/mL)
- Degarelix 240 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (60 mg/mL)
- Degarelix 320 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 320 mg (60 mg/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).